Duloxetine on Bone Metabolism

NCT05550506 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2022-09-22

No results posted yet for this study

Summary

The aim of the study was to determine the effect of duloxetine as monotherapy on biochemical markers and bone mineral density.

Conditions

Interventions

DRUG

Duloxetine

Patients who use duloxetine for chronic pain or fibromyalgia

Sponsors & Collaborators

  • Cukurova University

    lead OTHER

Principal Investigators

  • Burak Demir, Dr. · Cukurova University Faculty of Medicine Department of Physical Medicine and Rehabilitation

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2022-10-01
Completion
2022-12-25
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05550506 on ClinicalTrials.gov